Details of the Drug

General Information of Drug (ID: DMISH0Z)

Drug Name

Mogamulizumab

Indication

Disease Entry	ICD 11	Status	REF
Mycosis fungoides	2B01	Approved	[1]
Sezary syndrome	2B02	Approved	[1]
Cutaneous T-cell lymphoma	2B01	Phase 3	[2]
T-cell leukaemia	2A90	Phase 2	[2]
Solid tumour/cancer	2A00-2F9Z	Phase 1/2	[2]
------------------------------------------------------------------------------------

Drug Type

Monoclonal antibody

ADMET Property

Absorption AUC: The area under the plot of plasma concentration (AUC) of drug is 5577 mgh/L []
Absorption Cmax: The maximum plasma concentration (Cmax) of drug is 32 mg/L []
Clearance: The clearance of drug is 12 mL/h []
Half-life: The concentration or amount of drug in body reduced by one-half in 17 days []
Vd: The volume of distribution (Vd) of drug is 3.6 L []

Cross-matching ID

Repurposed Drugs (RPD)

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
C-C chemokine receptor type 4 (CCR4)	TT7HQD0	CCR4_HUMAN	Inhibitor	[3]

------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This Drug

Molecular Expression Atlas of This Drug

The Studied Disease

Mycosis fungoides

ICD Disease Classification

2B01

Molecule Name	Molecule Type	Gene Name	p-value	Fold-Change	Z-score
C-C chemokine receptor type 4 (CCR4)	DTT	CCR4	2.33E-02	3.98E-03	0.03

Molecular Expression Atlas (MEA)

Jump to Detail Molecular Expression Atlas of This Drug

Drug-Drug Interaction (DDI) Information of This Drug

Coadministration of a Drug Treating the Disease Different from Mogamulizumab (Comorbidity)

DDI Drug Name	DDI Drug ID	Severity	Mechanism	Comorbidity	REF
Ozanimod	DMT6AM2	Major	Additive immunosuppressive effects by the combination of Mogamulizumab and Ozanimod.	Multiple sclerosis [8A40]	[4]
-----------

References

1	2018 FDA drug approvals.Nat Rev Drug Discov. 2019 Feb;18(2):85-89.
2	Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
3	Mogamulizumab, a humanized mAb against C-C chemokine receptor 4 for the potential treatment of T-cell lymphomas and asthma. Curr Opin Mol Ther. 2010 Dec;12(6):770-9.
4	Cerner Multum, Inc. "UK Summary of Product Characteristics.".